Novel Therapies for Unmet Clinical Needs in Myelodysplastic Syndromes

Overview

Journal Cancers (Basel)

Publisher MDPI

Specialty Oncology

Date 2022 Oct 14

PMID 36230864

Authors

Giulio Cassanello

Raffaella Pasquale

Wilma Barcellini

Bruno Fattizzo

Affiliations

Soon will be listed here.

Abstract

Myelodysplastic syndromes (MDS) are a very heterogeneous disease, with extremely variable clinical features and outcomes. Current management relies on risk stratification based on IPSS and IPSS-R, which categorizes patients into low (LR-) and high-risk (HR-) MDS. Therapeutic strategies in LR-MDS patients mainly consist of erythropoiesis stimulating agents (ESAs), transfusion support, and luspatercept or lenalidomide for selected patients. Current unmet needs include the limited options available after treatment failure, and the consequent transfusion burden with several hospital admissions and poor quality of life. Therapeutic approaches in HR-MDS patients are aimed at changing the natural course of the disease and hypometylating agents (HMA) are the first choice. The only potentially curative treatment is allogeneic stem cell transplant (allo-HCT), restricted to a minority of young and fit candidates. Patients unfit for or those that relapse after the abovementioned options harbor an adverse prognosis, with limited overall survival and frequent leukemic evolution. Recent advances in genetic mutations and intracellular pathways that are relevant for MDS pathogenesis are improving disease risk stratification and highlighting therapeutic targets addressed by novel agents. Several drugs are under evaluation for LR and HR patients, which differ by their mechanism of action, reported efficacy, and phase of development. This review analyzes the current unmet clinical needs for MDS patients and provides a critical overview of the novel agents under development in this setting.

Citing Articles

Toward a more patient-centered drug development process in clinical trials for patients with myelodysplastic syndromes/neoplasms (MDS): Practical considerations from the International Consortium for MDS (icMDS).

Efficace F, Buckstein R, Abel G, Giesinger J, Fenaux P, Bewersdorf J Hemasphere. 2024; 8(5):e69.

PMID: 38774655 PMC: 11106800. DOI: 10.1002/hem3.69.

Unveiling sex-based geographical disparities in myelodysplastic syndrome mortality trends in Spain (1999-2022).

Martin-Rojas R, Cayuela L, Martin-Dominguez F, Cayuela A Clin Transl Oncol. 2024; 26(10):2693-2700.

PMID: 38762824 DOI: 10.1007/s12094-024-03503-7.

Long-term hematologic response after azacitidine treatment in a lower-risk myelodysplastic syndrome patient: A case report.

Loukidis K, Tschopp M Leuk Res Rep. 2024; 21:100412.

PMID: 38292515 PMC: 10825634. DOI: 10.1016/j.lrr.2024.100412.

The Importance of the Pyrazole Scaffold in the Design of Protein Kinases Inhibitors as Targeted Anticancer Therapies.

Nitulescu G, Stancov G, Seremet O, Nitulescu G, Mihai D, Duta-Bratu C Molecules. 2023; 28(14).

PMID: 37513232 PMC: 10385367. DOI: 10.3390/molecules28145359.

Impact of Next-Generation Sequencing in Diagnosis, Prognosis and Therapeutic Management of Acute Myeloid Leukemia/Myelodysplastic Neoplasms.

Madaci L, Farnault L, Abbou N, Gabert J, Venton G, Costello R Cancers (Basel). 2023; 15(13).

PMID: 37444390 PMC: 10339965. DOI: 10.3390/cancers15133280.

References

Stahl M, DeVeaux M, de Witte T, Neukirchen J, Sekeres M, Brunner A . The use of immunosuppressive therapy in MDS: clinical outcomes and their predictors in a large international patient cohort. Blood Adv. 2018; 2(14):1765-1772. PMC: 6058241. DOI: 10.1182/bloodadvances.2018019414. View

Kantarjian H, Giles F, Greenberg P, Paquette R, Wang E, Gabrilove J . Phase 2 study of romiplostim in patients with low- or intermediate-risk myelodysplastic syndrome receiving azacitidine therapy. Blood. 2010; 116(17):3163-70. PMC: 3324162. DOI: 10.1182/blood-2010-03-274753. View

Santini V, Almeida A, Giagounidis A, Gropper S, Jonasova A, Vey N . Randomized Phase III Study of Lenalidomide Versus Placebo in RBC Transfusion-Dependent Patients With Lower-Risk Non-del(5q) Myelodysplastic Syndromes and Ineligible for or Refractory to Erythropoiesis-Stimulating Agents. J Clin Oncol. 2016; 34(25):2988-96. DOI: 10.1200/JCO.2015.66.0118. View

Santini V, Valcarcel D, Platzbecker U, Komrokji R, Cleverly A, Lahn M . Phase II Study of the ALK5 Inhibitor Galunisertib in Very Low-, Low-, and Intermediate-Risk Myelodysplastic Syndromes. Clin Cancer Res. 2019; 25(23):6976-6985. DOI: 10.1158/1078-0432.CCR-19-1338. View

Yang L, Qian Y, Eksioglu E, Epling-Burnette P, Wei S . The inflammatory microenvironment in MDS. Cell Mol Life Sci. 2015; 72(10):1959-66. PMC: 11113192. DOI: 10.1007/s00018-015-1846-x. View

Yang H, Bueso-Ramos C, DiNardo C, Estecio M, Davanlou M, Geng Q . Expression of PD-L1, PD-L2, PD-1 and CTLA4 in myelodysplastic syndromes is enhanced by treatment with hypomethylating agents. Leukemia. 2013; 28(6):1280-8. PMC: 4032802. DOI: 10.1038/leu.2013.355. View

Bewersdorf J, Zeidan A . Transforming growth factor (TGF)-β pathway as a therapeutic target in lower risk myelodysplastic syndromes. Leukemia. 2019; 33(6):1303-1312. DOI: 10.1038/s41375-019-0448-2. View

Kelaidi C, Park S, Brechignac S, Mannone L, Vey N, Dombret H . Treatment of myelodysplastic syndromes with 5q deletion before the lenalidomide era; the GFM experience with EPO and thalidomide. Leuk Res. 2008; 32(7):1049-53. DOI: 10.1016/j.leukres.2007.11.037. View

Marvin-Peek J, Savani B, Olalekan O, Dholaria B . Challenges and Advances in Chimeric Antigen Receptor Therapy for Acute Myeloid Leukemia. Cancers (Basel). 2022; 14(3). PMC: 8833567. DOI: 10.3390/cancers14030497. View

10.

Bernard E, Tuechler H, Greenberg P, Hasserjian R, Arango Ossa J, Nannya Y . Molecular International Prognostic Scoring System for Myelodysplastic Syndromes. NEJM Evid. 2024; 1(7):EVIDoa2200008. DOI: 10.1056/EVIDoa2200008. View

11.

Kubasch A, Schulze F, Giagounidis A, Gotze K, Kronke J, Sockel K . Single agent talacotuzumab demonstrates limited efficacy but considerable toxicity in elderly high-risk MDS or AML patients failing hypomethylating agents. Leukemia. 2019; 34(4):1182-1186. PMC: 7214242. DOI: 10.1038/s41375-019-0645-z. View

12.

Fenaux P, Mufti G, Hellstrom-Lindberg E, Santini V, Finelli C, Giagounidis A . Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study. Lancet Oncol. 2009; 10(3):223-32. PMC: 4086808. DOI: 10.1016/S1470-2045(09)70003-8. View

13.

Buesche G, Teoman H, Wilczak W, Ganser A, Hecker H, Wilkens L . Marrow fibrosis predicts early fatal marrow failure in patients with myelodysplastic syndromes. Leukemia. 2007; 22(2):313-22. DOI: 10.1038/sj.leu.2405030. View

14.

Temraz S, Santini V, Musallam K, Taher A . Iron overload and chelation therapy in myelodysplastic syndromes. Crit Rev Oncol Hematol. 2014; 91(1):64-73. DOI: 10.1016/j.critrevonc.2014.01.006. View

15.

Ades L, Itzykson R, Fenaux P . Myelodysplastic syndromes. Lancet. 2014; 383(9936):2239-52. DOI: 10.1016/S0140-6736(13)61901-7. View

16.

Mendez L, Posey R, Pandolfi P . The Interplay Between the Genetic and Immune Landscapes of AML: Mechanisms and Implications for Risk Stratification and Therapy. Front Oncol. 2019; 9:1162. PMC: 6856667. DOI: 10.3389/fonc.2019.01162. View

17.

Khoury J, Solary E, Abla O, Akkari Y, Alaggio R, Apperley J . The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Myeloid and Histiocytic/Dendritic Neoplasms. Leukemia. 2022; 36(7):1703-1719. PMC: 9252913. DOI: 10.1038/s41375-022-01613-1. View

18.

Steensma D, Wermke M, Klimek V, Greenberg P, Font P, Komrokji R . Phase I First-in-Human Dose Escalation Study of the oral SF3B1 modulator H3B-8800 in myeloid neoplasms. Leukemia. 2021; 35(12):3542-3550. PMC: 8632688. DOI: 10.1038/s41375-021-01328-9. View

19.

Angelucci E, Li J, Greenberg P, Wu D, Hou M, Montano Figueroa E . Iron Chelation in Transfusion-Dependent Patients With Low- to Intermediate-1-Risk Myelodysplastic Syndromes: A Randomized Trial. Ann Intern Med. 2020; 172(8):513-522. DOI: 10.7326/M19-0916. View

20.

Neukirchen J, Schoonen W, Strupp C, Gattermann N, Aul C, Haas R . Incidence and prevalence of myelodysplastic syndromes: data from the Düsseldorf MDS-registry. Leuk Res. 2011; 35(12):1591-6. DOI: 10.1016/j.leukres.2011.06.001. View